Stay updated with breaking news from Exosome therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is excited to announce excited to announce that Dr. Lior Shaltiel, CEO of NurExone Biologic, will be presenting advances in exosome-based therapy for spinal cord injury (SCI) and other traumatic central nervous sys ....
/PRNewswire/ The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2023" report has been added to ResearchAndMarkets.com s offering.. ....
DUBLIN (BUSINESS WIRE) The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2023" report has been added to ResearchAndMarkets.com's offering.Globally, there are at least 204 clinical trials focusing on exosome-related studies. Of these, 114 trials are evaluating exosome-based therapeutics an. ....
An Incurable Disease With A Hefty Treatment Cost Motivated Him To Start A Business forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Apr 12, 2021 Critically, the University’s ability to do deep analysis of miRNA content enabled VivaZome to link exosome content to biological activity and so to potential clinical application. Professor Hill, Associate Provost of Research and Industry Engagement at La Trobe said: “It is exciting to extend our CRC-Project into a new research relationship and to use our expertise in exosome analytics and characterisations to contribute to the success of VivaZome’s development program. We look forward to working with VivaZome and their national and international collaborators.” VivaZome‘s Chief Executive Officer, Dr David Haylock, said: “VivaZome is delighted to enter in to this new, post-CRC-P partnership with La Trobe and to extend its productive relationship with Professor Hill and his research team. As VivaZome broadens its portfolio of activity to encompass ischaemia, fibrotic diseases and neurological disorders, La Trobe’s world-class capability will ....